MicroRNAs as Bile-Based Biomarkers in Pancreatic Cancer and Biliary Tract Cancers
Poster May 09, 2017
M. Mato Prado*1, A. E. Frampton*1,2, N. Funel3,4, E. Lopez-Jimenez1, L. Castellano1, P. Lawton1, L. L. Meijer5, G. Kazemier5, L. R. Jiao2, J. Stebbing*1, E. Giovannetti*4,6, J. Krell*1
Pancreatic cancer is one of the most lethal diseases in the world with 9,618 new cases and around 8,800 deaths in the UK. It is the fourth most common cause of cancer death in the UK (2014). The lack of efficient diagnostic techniques and limited treatment options leads to a late detection and poor survival rates (less than 1%)1.Therefore, further investigation is needed to improve the detection process and design specific molecular targeted treatments.
During last decade, a class of non-coding RNAs (microRNAs) are emerging as potential biomarkers and therapeutic targets for different cancers. In this study, the role of miRNAs has been assessed in a large cohort of pancreatic cancer.
Analysis of the Effect of Aggregated β-Amyloid on Cellular Signaling Pathways Critical for Memory in Alzheimer’s DiseasePoster
Here we evaluate the ability to detect changes in phosphorylation levels of ERK and CREB following treatment with Aβ using the SH-SY5Y neuroblastoma cell line.READ MORE
Complete alignment identification of CRISPR-Cas9 genomic off-targets using Edit-R CRISPR specificity tool and a comprehensive analysis of positional mismatch tolerancePoster
A web tool that performs complete crRNA specificity checking is introduced. In addition, we evaluated positional off-targeting of the CRISPR system.READ MORE
Is Oxford Nanopore Technology Ready for Clinical Diagnostics?Poster
Our objective is to validate diagnostic services using Oxford Nanopore’s Minion in the first instance and to evaluate the cost and performance compared to existing sequencing technology in areas such as tumour DNA sequencing (and circulating tumour DNA), virology, microbiology, genetics and HLA-typing.READ MORE